D Boral Capital Upgrades CERo Therapeutics (NASDAQ:CERO) to Strong-Buy

D Boral Capital upgraded shares of CERo Therapeutics (NASDAQ:CERO) to a strong-buy rating in a research report released on Tuesday morning,Zacks.com reports.

Separately, D. Boral Capital assumed coverage on CERo Therapeutics in a report on Tuesday. They set a “buy” rating and a $11.00 target price on the stock.

CERo Therapeutics Trading Up 5.5 %

Shares of CERO opened at $0.80 on Tuesday. CERo Therapeutics has a 52-week low of $0.53 and a 52-week high of $171.00. The firm has a 50-day moving average price of $1.08 and a 200 day moving average price of $6.07.

Institutional Investors Weigh In On CERo Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ARCH Venture Management LLC grew its stake in shares of CERo Therapeutics by 550.4% in the 4th quarter. ARCH Venture Management LLC now owns 9,393,561 shares of the company’s stock worth $564,000 after purchasing an additional 7,949,265 shares during the last quarter. Avantax Planning Partners Inc. grew its position in CERo Therapeutics by 89.9% in the fourth quarter. Avantax Planning Partners Inc. now owns 2,585,151 shares of the company’s stock worth $155,000 after buying an additional 1,224,021 shares during the last quarter. Finally, Parallel Advisors LLC bought a new position in shares of CERo Therapeutics in the first quarter valued at $161,000. 29.64% of the stock is owned by institutional investors and hedge funds.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.